3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Colorectal Neoplasms
63
Colonic Neoplasms
29
Rectal Neoplasms
25
Neoplasm Metastasis
11
Stomach Neoplasms
8
Carcinoma, Hepatocellular
7
Pancreatic Neoplasms
6
Neoplasms
6
Esophageal Neoplasms
4
Adenocarcinoma Of Esophagus
4
Liver Neoplasms
3
Ovarian Neoplasms
2
Esophageal Squamous Cell Carcinoma
2
Recurrence
1
Prostatic Neoplasms
1
Postoperative Complications
1
Peritoneal Neoplasms
1
Operable T2-3N+M0 Rectal Cancer (Stage III)
1
Neuropathy, Painful
1
Neuralgia
1
Neoplasm Recurrence, Local
1
Melanoma
1
Malignant Solid Tumour
1
Locally Advanced Pancreatic Carcinoma(LAPC)
1
Gastrointestinal Neoplasms
1
Cold Hypersensitivity
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Basal Cell
1
Interventions
Ipilimumab
114
pembrolizumab
95
Nivolumab
91
aldesleukin
86
Interleukin-2
57
Cyclophosphamide
54
Dacarbazine
52
Vemurafenib
39
trametinib
37
Temozolomide
37
incomplete Freund's adjuvant
35
fludarabine phosphate
35
sargramostim
32
dabrafenib
32
fludarabine
26
Bevacizumab
26
Paclitaxel
22
MART-1 Antigen
21
Granulocyte-Macrophage Colony-Stimulating Factor
21
montanide ISA 51
20
Interferon-alpha
20
Cisplatin
20
Carboplatin
19
Sorafenib
18
Introns
17
Biopsy
17
cobimetinib
16
Radiosurgery
16
atezolizumab
15
Radiotherapy
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Melanoma
×
Folfox protocol
×
Clear all
NCT02009449
2024-11-15
IVY
Eli Lilly and Company
Phase 1
Completed
353 enrolled